Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pasireotide in Prevention of GI Toxicity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02215070
Recruitment Status : Completed
First Posted : August 13, 2014
Results First Posted : March 11, 2020
Last Update Posted : March 27, 2020
Sponsor:
Collaborator:
Massachusetts General Hospital
Information provided by (Responsible Party):
Anthony Sung, MD, Duke University

Brief Summary:
The purpose of this study is to evaluate if the drug, Pasireotide, is safe and effective in reducing the gastrointestinal side effects of the drugs received to prepare for allogeneic stem cell transplant. The study will also evaluate if Pasireotide is effective in reducing acute and chronic Graft-versus-Host-Disease (GvHD) after transplant.

Condition or disease Intervention/treatment Phase
Hematological Malignancies Drug: Pasireotide Phase 2

Detailed Description:

The study design will be a non-randomized phase II. Forty patients receiving an ablative preparatory regimen will receive pasireotide subcutaneous (0.9 mg, b.i.d.) one day prior to initiation of the preparatory regimen and continuing for eight days following the completion of the preparatory regimen not to exceed 14 days total dosing. We select matched controls from existing patients who did not take the drug to minimize the time it takes to complete the trial.

Myeloablative preparatory regimens are defined as those including either TBI ≥ 1200 cGy or busulfan ≥ 12.8 mg/kg. The most common regimens combine TBI with cyclophosphamide (TBI/Cy) or busulfan with cyclophosphamide (Bu/Cy) (Appendix E). However, any regimen meeting the above definition of myeloablative preparatory regimen may be used.

The study will collect data at screening, at baseline prior to initiation of the drug (day of study drug start), transplant day 0, day +7, day +14 and weekly thereafter until day +100, and on days +180, +270, and +365. The total days on pasireotide therapy will be recorded as well as any SAE that is outside the expected for stem cell transplantation. We will also follow the incidence and severity of acute and chronic GVHD.

At Duke only, a video capsule endoscopy will be performed in a subset of ten study patients between transplant days +4 through +6. This substudy is descriptive in nature and only used to collect a source of preliminary data that may suggest further study.

Patients must agree to participate in this portion of the study and will be asked to sign a clinical consent for performance use of the video capsule endoscopy. Patients will be given detailed instructions to prepare for the procedure. An investigator who is blinded to the group allocation of the patients/volunteers separately will review the images obtained from each of the capsule examinations. Images will be examined for evidence of the four following types of abnormalities: reddened/edema/villous blunting, erosion, ulcer and stenosis. Each of these categories will be scored from 0-3 and summed to obtain an overall index that will range from 0 (normal study) to 12 (severely abnormal in all categories).

Citrulline assay Measurement of citrulline concentration has been used as a marker for cytotoxic treatment-induced intestinal damage and it is highly reproducible. The citrulline concentration appears to be a quantitative parameter that is independent of the underlying cause for epithelial cell loss and functions well in the post-SCT setting. Six mls of blood will be collected in heparinized tubes on days 0, 7, and 14. Tubes will be centrifuged according to manufacturer's instructions and the plasma will be collected and stored at -80C until shipment to the laboratory performing the assay.

Calprotectin assay Calprotectin has been described as another biomarker of GI injury. During radiation-induced inflammation, leucocytes infiltrate the mucosa and increase the level of fecal calprotectin. At least 50 mg of stool specimen will be collected from patients on days 0, 7, and 14. Samples will be stored at -80C until shipment to the laboratory performing the assay. Calprotectin will be measured with an ELISA kit (CALPRO, Oslo, Norway) in accordance with the manufacturer's instructions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide
Actual Study Start Date : January 21, 2015
Actual Primary Completion Date : February 28, 2019
Actual Study Completion Date : October 15, 2019


Arm Intervention/treatment
Experimental: Pasireotide + Preparatory Regimen
Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
Drug: Pasireotide
Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.




Primary Outcome Measures :
  1. Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide [ Time Frame: 30 Days ]
    Number of participants who experience grades III-IV GI toxicity


Secondary Outcome Measures :
  1. Percentage of Acute GVHD [ Time Frame: 100 days ]
    Number of participants who experience acute GVHD

  2. Maximum Severity of Acute GVHD Compared to Historical Controls [ Time Frame: 100 days ]
    Assess maximum severity of acute GVHD scored as stage 1 (least severe) through stage 4 (most severe) using BMT CTN, 2013 standards

  3. Incidence of Chronic GVHD Compared to Historical Controls [ Time Frame: 1 year ]
    Measure the number of participants who experience chronic GVHD

  4. Maximum Severity of Chronic GVHD Compared to Historical Controls [ Time Frame: 1 year ]
    Assess maximum severity of chronic GVHD scored as none, mild, moderate or severe using 2014 NIH Consensus Criteria

  5. Overall Survival Compared to Historical Controls [ Time Frame: 1 year ]
    Rate of overall survival of participants at one year post transplant

  6. Disease Free Survival Compared to Historical Controls [ Time Frame: 1 year ]
    Rate of disease free survival of participants at one year post transplant


Other Outcome Measures:
  1. Citrulline and Fecal Calprotectin Levels Will be Measured [ Time Frame: 100 days ]
    Exploratory outcome-These levels will be evaluated as biomarkers of GI tract health and function in SCT patients and the correlation between these biomarkers and GI toxicity.

  2. Evaluate GI Toxicity Assessment by Video Capsule Endoscopy. [ Time Frame: 14 days ]
    Exploratory outcome-Video capsule endoscopy will be performed in a subset of ten study participants on the last day study drug is administered. Images will be examined for evidence of the four following types of abnormalities: reddened/edema/villous blunting, erosion, ulcer and stenosis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older at the time of study enrollment.
  • Histologically confirmed diagnosis for which an allogeneic transplant is utilized.
  • Plan to receive an allogeneic transplant from a 4-6/6 single or dual umbilical cord blood graft, or a 7-8/8 HLA-matched sibling or unrelated donor (High resolution HLA-A, B, C, DRB1).
  • Meet standard criteria as defined by the institution for a myeloablative allogeneic stem cell transplantation, with myeloablative defined as using conditioning regimens containing:

    • TBI ≥ 1200 cGy, or
    • Busulfan ≥ 12.8mg/kg
  • Patient must have given written informed consent according to FDA guidelines.
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.

Exclusion Criteria:

  • Female patients who are pregnant or lactating, or are of childbearing potential (FCBP, defined as all women physiologically capable of becoming pregnant) and not practicing an effective method of contraception/birth control
  • FCBP must have a current negative serum pregnancy test prior to transplant per institutional practice.
  • Use of an investigational drug within 1 month prior to dosing. Concurrent enrollment on other clinical research studies that contain an interventional therapy is not permitted while subjects are receiving pasireotide or within 5 half-lives of finishing pasireotide. However, subjects may concurrently enroll in non-interventional studies (e.g. biobanking, mobile health tracking).
  • Active CNS disease (related to primary malignancy) at the time of enrollment.
  • Patients with existing grade 2 toxicities, except as approved by the investigator.
  • Any of the following diseases or conditions:

Cardiac:

  • History of unexplained syncope or family history of idiopathic sudden death.
  • Sustained or clinically significant cardiac arrhythmias.
  • Risk factors for Torsades de Pointes such as:

    • Uncontrolled hypokalemia
    • Uncontrolled hypomagnesemia or hypermagnesemia
    • Cardiac failure (New York Heart Association Class II or higher)
    • Clinically significant/symptomatic bradycardia (HR < 50), or high-grade AV block.
    • Known diagnosis of QT prolongation (QTc ≥ 470) or family history of long QT syndrome
    • Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure.
    • Concomitant medications known to prolong the QT interval during the same time as pasireotide is to be administered (unless approved by PI and QTc < 470; standard transplant medications that are known to prolong the QT (e.g. azoles, ondansetron, etc.) are permitted but caution is advised and patients should be closely monitored).

Endocrine:

  • Uncontrolled diabetes at the time of cytoreduction. All patients with diabetes must be optimized on their diabetes regimen prior to initiating pasireotide.

    • If a patient is diabetic: uncontrolled diabetes as defined by HbA1c > 8 per cent despite adequate therapy

  • Patients who are not biochemically euthyroid. Patients with known history of hypothyroidism are eligible if they are on adequate and stable replacement thyroid hormone therapy for at least 3 months.
  • Known diagnosis of hypocortisolism
  • Known diagnosis of pituitary hormone deficiency.
  • Known hypersensitivity to somatostatin analogs or any component of the pasireotide LAR or s.c. formulations.

Infectious:

  • Uncontrolled (not being treated) infections at the time of cytoreduction.
  • A positive HIV test result (ELISA and Western blot) or history of known HIV. An HIV test will not be required; however, previous medical history will be reviewed.

Gastrointestinal:

  • Moderately impaired hepatic function (Child-Pugh B) or severe hepatic impairment (Child-Pugh C)
  • Known gallbladder or bile duct disease, symptomatic cholelithiasis, acute or chronic pancreatitis.
  • Known malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means.

Hematologic:

  • Abnormal coagulation (PT or aPTT > 30% above normal limits).
  • Continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a washout period of at least 10 days and have confirmed normal coagulation parameters before study inclusion.

Miscellaneous:

  • Major surgery/surgical therapy for any cause within 1 month prior to pasireotide administration. Patients should have recovered and have a good clinical condition before entering the study.
  • Any co-morbid condition which, in the view of the Principal Investigator, renders the patient at high risk from treatment complications.

Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02215070


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Anthony Sung, MD
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Anthony Sung, MD Duke University
  Study Documents (Full-Text)

Documents provided by Anthony Sung, MD, Duke University:

Layout table for additonal information
Responsible Party: Anthony Sung, MD, Professor of Medicine, Duke University
ClinicalTrials.gov Identifier: NCT02215070    
Other Study ID Numbers: Pro00051736
First Posted: August 13, 2014    Key Record Dates
Results First Posted: March 11, 2020
Last Update Posted: March 27, 2020
Last Verified: March 2020
Keywords provided by Anthony Sung, MD, Duke University:
Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia
Acute Lymphoid Leukemia
Acute Non-Lymphocytic Leukemia
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pasireotide
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs